Phio Pharmaceuticals Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.42next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
PH-762 Pathological Response Rate in cSCC (Highest Dose Cohort) Annually85.0%Target: 80 or higher%
Cash and Cash Equivalents (USD Millions) Quarterly17.0Target: Maintain runway into H1 2027
Number of Active Clinical Programs Annually1Target: 2.0 (Advance PH-894 to clinic)
Watch Items
- FDA feedback on next-stage clinical study design for PH-762Trigger: Receipt of official FDA meeting minutes or guidance documentAction: Review protocol requirements, finalize toxicology study design, and prepare IND amendment or Phase 2 trial protocol.
- Cash runway depletion and capital requirementsTrigger: Cash balance falling below $10.0 millionAction: Evaluate utilization of the $6.36 million at-the-market (ATM) equity program or seek strategic partnerships.
- Non-clinical toxicology study completion for PH-762Trigger: Final toxicology report delivery from contract laboratoryAction: Submit toxicology data package to the FDA to support pivotal clinical development.
Research as of 20 Jun 2026